STA
MRVI icon

Summit Trail Advisors’s Maravai LifeSciences MRVI Stock Holding History

Summit Trail Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
73,931
-6,518
-8% -$22.1K ﹤0.01% 1369
2025
Q4 		$261K Sell
80,449
-4,926
-6% -$16.6K ﹤0.01% 1229
2025
Q3 		$245K Buy
85,375
+737
+0.9% +$1.88K ﹤0.01% 1247
2025
Q2 		$204K Buy
+84,638
New +$178K ﹤0.01% 1058

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Trail Advisors's MRVI Position: Q1 2026 in Review

Summit Trail Advisors reduced its Maravai LifeSciences (MRVI) stake by 8.1% in Q1 2026, selling an estimated $22.1K and leaving 73,931 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #1369.

Summit Trail Advisors first reported a position in MRVI in Q2 2025 and has held it in 4 quarters since. The position peaked at $261K in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Summit Trail Advisors held 73,931 shares of Maravai LifeSciences worth $209K as of Q1 2026.
  • Summit Trail Advisors sold 6,518 Maravai LifeSciences shares in Q1 2026, an estimated $22.1K.
  • Maravai LifeSciences made up ﹤0.01% of Summit Trail Advisors's portfolio in Q1 2026, its #1369 holding.
  • Summit Trail Advisors first reported a position in Maravai LifeSciences in Q2 2025 and has held it in 4 quarters since.
  • Summit Trail Advisors's Maravai LifeSciences position peaked at $261K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.